<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1525">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05141305</url>
  </required_header>
  <id_info>
    <org_study_id>MK02-2020-02</org_study_id>
    <nct_id>NCT05141305</nct_id>
  </id_info>
  <brief_title>Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-III</brief_title>
  <acronym>TRACEIII</acronym>
  <official_title>A Phase 3, Multicenter, Prospective, Randomized, Open Label, Blinded-endpoint (PROBE) Controlled Trial of Recombinant Human TNK Tissue-type Plasminogen Activator (rhTNK-tPA) for Injection Versus Standard Medical Treatment for Acute Ischemic Stroke Due to Large Vessel Occlusion With Perfusion Mismatch up to 24 Hours of Symptom Onset</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is a multicenter, prospective, block randomized, open label, blinded-endpoint&#xD;
      (PROBE) controlled design. Patients with acute ischemic stroke due to large vessel occlusion&#xD;
      within 4.5-24 hours of symptom onset (including wake-up stroke and unwitnessed stroke) will&#xD;
      be randomized 1:1 to 0.25mg/kg intravenous tenecteplase or standard medical treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be a multicenter, prospective, randomized, open label, blinded-endpoint&#xD;
      (PROBE), controlled phase 3 trial (2 arms with 1:1 randomization) in ischemic stroke due to&#xD;
      large vessel occlusion with perfusion mismatch up to 24 hours of symptom onset. The target&#xD;
      mismatch profiles on CTP or MRI perfusion weighted imaging include ischemic core volume &lt;70&#xD;
      mL, mismatch ratio≥1.8 and mismatch volume≥15 mL demonstrated by a certified automatic&#xD;
      software. The sample size is 516 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2022</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Excellent functional outcome</measure>
    <time_frame>90 days</time_frame>
    <description>Excellent functional outcome defined as an mRS score ≤ 1 at 90 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response rate at 72h</measure>
    <time_frame>72 hours</time_frame>
    <description>Clinical response rate at 72h defined as an improvement on NIHSS score ≥ 8 points compared with the initial deficit or a score ≤ 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Favorable functional outcome</measure>
    <time_frame>90 days</time_frame>
    <description>Favorable functional outcome defined as an mRS score ≤ 2 point at 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ordinal distribution of mRS</measure>
    <time_frame>90 days</time_frame>
    <description>Ordinal distribution of mRS at 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of improvement on reperfusion</measure>
    <time_frame>24 hours</time_frame>
    <description>The rate of improvement on reperfusion at 24h (improved by 90% on Tmax&gt;6s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIHSS change from baseline</measure>
    <time_frame>7 days</time_frame>
    <description>NIHSS change from baseline at 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic intracranial hemorrhage</measure>
    <time_frame>36 hours</time_frame>
    <description>Symptomatic intracranial hemorrhage within 36 hours ( as defined by ECASSIII )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days</time_frame>
    <description>Mortality at 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systematic bleeding</measure>
    <time_frame>90 days</time_frame>
    <description>Systematic bleeding at 90 days ( as defined by GUSTO: moderate and severe bleeding )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events ( AEs ) / serious adverse events ( SAEs )</measure>
    <time_frame>90 days</time_frame>
    <description>Adverse events ( AEs ) / serious adverse events ( SAEs ) within 90 days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">516</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>rhTNK-tPA ( 0.25 mg/kg, Max 25 mg )</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rhTNK-tPA ( 0.25 mg/kg ) is given as a single, intravenous bolus ( within 5-10 seconds ) immediately upon randomization. Maximum dose 25mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard medical treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone after randomization at the discretion of local neurologists</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhTNK-tPA ( 0.25 mg/kg, Max 25 mg )</intervention_name>
    <description>rhTNK-tPA (0.25 mg/kg) is being used.</description>
    <arm_group_label>rhTNK-tPA ( 0.25 mg/kg, Max 25 mg )</arm_group_label>
    <other_name>TNK-tPA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard medical treatment</intervention_name>
    <description>Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone are being used.</description>
    <arm_group_label>standard medical treatment</arm_group_label>
    <other_name>Aspirin, Clopidogrel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1) Age ≥18 years; 2) Acute ischemic stroke symptom onset between 4.5 to 24 hours prior&#xD;
             to enrollment; including wake-up stroke and unwitnessed stroke, onset time refers to&#xD;
             'last normal time'; 3) Pre-stroke mRS score≤1; 4) Baseline NIHSS 6-25 ( both included&#xD;
             ); 5) Neuroimaging: Internal carotid artery, middle cerebral artery M1 or M2 occlusion&#xD;
             confirmed by CTA/MRA ( carotid artery occlusion refers to carotid artery or&#xD;
             intracranial artery, with or without tandem occlusion ), and target mismatch profile&#xD;
             on CT perfusion ( CTP ) or MRI_perfusion weighted imaging ( MRI_PWI ) including&#xD;
             ischemic core volume &lt;70 mL, mismatch ratio≥1.8 and mismatch volume≥15 mL demonstrated&#xD;
             by a certified automatic software; 6) written informed consent from patients or their&#xD;
             legally authorized representatives.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1) Intended to proceed to endovascular treatment; 2) Allergy to rhTNK-tPA; 3) Rapidly&#xD;
             improving symptoms at the discretion of the investigator; 4) NIHSS consciousness score&#xD;
             1a &gt;2, or epileptic seizure, hemiplegia after seizures ( Todd's palsy ) or combined&#xD;
             with other nervous/mental illness not able to cooperate or unwilling to cooperate; 5)&#xD;
             Persistent blood pressure elevation ( systolic ≥180 mmHg or diastolic ≥100 mmHg ),&#xD;
             despite blood pressure lowering treatment; 6) Blood glucose &lt;2.8 or &gt;22.2 mmol/L ( on&#xD;
             random glucose testing is acceptable ); 7) Active internal bleeding or at high risk of&#xD;
             bleeding, e.g.: Major surgery, trauma or gastrointestinal or urinary tract haemorrhage&#xD;
             within the previous 21 days, or arterial puncture at a non-compressible site within&#xD;
             the previous 7 days; 8) Any known impairment in coagulation due to comorbid disease or&#xD;
             anticoagulant use. If on warfarin, then INR &gt;1.7 or prothrombin time &gt;15 seconds; if&#xD;
             use of any direct thrombin inhibitors or direct factor Xa inhibitors during the last&#xD;
             48 hours unless reversal of effect can be achieved with a reversal agent; if on any&#xD;
             full dose heparin/heparinoid during the last 24 hours or with an elevated aPTT greater&#xD;
             than the upper limit of normal; 9) Known defect of platelet function or platelet count&#xD;
             below 100,000/mm3 ( but patients on antiplatelet agents can be included ); 10)&#xD;
             Ischemic stroke or myocardial infarction in previous 3 months, previous intracranial&#xD;
             haemorrhage, severe traumatic brain injury or intracranial or intraspinal operation in&#xD;
             previous 3 months, or known intracranial neoplasm, arteriovenous malformation or giant&#xD;
             aneurysm; 11) Any terminal illness such that patient would not be expected to survive&#xD;
             more than 1 year; 12) Unable to perform CTP or PWI; 13) Hypodensity in &gt;1/3 MCA&#xD;
             territory on non-contrast CT; 14) Acute or past intracerebral hemorrhage ( ICH )&#xD;
             identified by CT or MRI; 15) Multiple arterial occlusion ( bilateral MCA occlusion,&#xD;
             MCA occlusion accompanied with basilar occlusion ); 16) Pregnant women, nursing&#xD;
             mothers, or reluctant to agree taking effective contraceptive measures during the&#xD;
             period of trial subjects; 17) Unlikely to adhere to the trial protocol or follow-up;&#xD;
             18) Any condition that, in the judgment of the investigator could impose hazards to&#xD;
             the patient if study therapy is initiated or affect the participation of the patient&#xD;
             in the study; 19) Participation in other interventional clinical trials within the&#xD;
             previous 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yunyun Xiong, MD</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yongjun Wang, MD, PhD</last_name>
    <phone>86-13911172565</phone>
    <email>yongjunwang111@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yunyun Xiong, MD, PhD</last_name>
    <phone>86-15710088948</phone>
    <email>xiongyunyun@bjtth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yongjun Wang, MD, PhD</last_name>
      <phone>13911172565</phone>
      <email>yongjunwang111@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 19, 2021</study_first_submitted>
  <study_first_submitted_qc>November 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2021</study_first_posted>
  <last_update_submitted>November 19, 2021</last_update_submitted>
  <last_update_submitted_qc>November 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Yongjun Wang</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>TNK-tPA, rt-PA, Acute stroke, phase III trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

